News

Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development

NEW YORK, NY (Newswire.com)— TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a study of investigational candidate, MYK-491, …

READ MORE

TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay: In Vitro Assay Accelerates Drug Development in Human-Relevant Heart Models

​​ TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…

READ MORE

Heart-on-a-Chip Mimics Drug Response Seen in Humans: In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery

NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The

READ MORE

TARA Secures Exclusive Worldwide License to Columbia University Intellectual Property relating to Engineered Human Cardiac Tissues

NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …

READ MORE

TARA Announces Issuance of US Patent for Biowire™ II Platform

New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …

READ MORE